✦ LIBER ✦

Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized Study

✍ Scribed by Hendrik W. Reesink; Stefan Zeuzem; Christine J. Weegink; Nicole Forestier; Andre van Vliet; Jeroen van de Wetering de Rooij; Lindsay McNair; Susan Purdy; Robert Kauffman; John Alam; Peter L.M. Jansen

Book ID: 119759404
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 262 KB
Volume: 131
Category: Article
ISSN: 0016-5085
DOI: 10.1053/j.gastro.2006.07.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 1, randomized, placebo-controlle

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C

✍ Eric J. Lawitz; Daniel Gruener; John M. Hill; Thomas Marbury; Lisa Moorehead; An 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 830 KB

Minimal Dose Interferon Suppository Trea

Minimal Dose Interferon Suppository Treatment Suppresses Viral Replication with Platelet Counts and Serum Albumin Levels Increased in Chronically Hepatitis C Virus-Infected Patients: A Phase 1b, Placebo-Controlled, Randomized Study

✍ Haruna, Yoshimichi; Inoue, Atsuo 📂 Article 📅 2014 🏛 Mary Ann Liebert 🌐 English ⚖ 266 KB

A Phase II, Randomized, Double-Blind, Pl

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide Plus Peginterferon and Ribavirin in Naïve Patients With Chronic Hepatitis C Genotype 1 Infection: Final Report

✍ Bruce R. Bacon; Mitchell L. Shiffman; Joseph K. Lim; Arthur Berman; Vinod K. Rus 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 90 KB

Sa1319 A Phase II, Randomized, Placebo-C

Sa1319 A Phase II, Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Antifibrotic Activity of Fuzheng Huayu in Chronic Hepatitis C Patients With Hepatic Fibrosis (S-USIIT-01)

✍ Hassanein, Tarek; Box, Terry D.; Tong, Myron J.; Pozza, Renee; Rossaro, Lorenzo; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 94 KB

Rationale and design of the EMBRACE STEM

Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction

✍ Chakrabarti, Anjan K.; Feeney, Kristin; Abueg, Cassandra; Brown, David A.; Czyz, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 322 KB

A phase II randomized, double-blind, pla

A phase II randomized, double-blind, placebo-controlled multicenter study of recombinant human interleukin-12 for the treatment of chronic hepatitis C virus infection in patients non-responsive to previous treatment with interferon-alpha with or without ribavirin: Paul J Pockros, John G McHutchison, Scripps Clinic, La Jolla, CA; Chris O'Brien, University of Miami, Miami, FL; Myron Tong, Huntingon Medical Research Institute, Pasadena, CA; Coleman Smith, Minnesota Clinical Research Center, St. Paul, MN; Vinod Rustgi, Metropolitan Research Group, Fairfax, VA; Robert L Carithers, University of Washington Medical Center, Seattle, WA; Elizabeth Olek, Genetics Institute, Cambridge, MA

📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB